NSCLC is the most common type of lung cancer accounting for approximately 85% of all lung cancers (roughly 509,000 incident cases in 2019 [7MM: the US, EU4 and the UK, and Japan]). The real-world treatment trend depicts a significant shift towards targeted and immunotherapies (from only systemic therapies in the past), which is expected to contribute to the evolution of the NSCLC treatment Paradigm. The existing NSCLC treatment is mainly dominated by checkpoint inhibitors such as KEYTRUDA and OPDIVO. Regarding EGFR-positive NSCLC market size, third-generation EGFRs such as AstraZeneca’s TAGRISSO are expected to dominate. In biomarker-specific NSCLC cases, the most num...
